Assil I Q, Abou-Samra A B
Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
Am J Physiol Endocrinol Metab. 2001 Nov;281(5):E1015-21. doi: 10.1152/ajpendo.2001.281.5.E1015.
The corticotropin-releasing factor (CRF) receptor type 1 (CRFR1) contains five potential N-glycosylation sites: N38, N45, N78, N90, and N98. Cells expressing CRFR1 were treated with tunicamycin to block receptor glycosylation. The nonglycosylated receptor did not bind the radioligand and had a decreased cAMP stimulation potency in response to CRF. To determine which of the polysaccharide chain(s) is/are involved in ligand interaction, the polysaccharide chains were deleted using site-directed mutagenesis of the glycosylation consensus, N-X-S/T. Two sets of mutations were performed for each glycosylation site: N to Q and S/T to A, respectively. The single mutants Q38, Q45, Q78, Q90, Q98, A40, A47, A80, A92, and A100 and the double mutants A40/A47 and A80/A100 were well expressed, bound CRF, sauvagine (SVG), and urotensin-I (UTS-I) with a normal affinity, and increased cAMP accumulation with a high efficiency. In contrast, the combined mutations A80/A92/A100, A40/A80/A92/A100, and A40/A47/A80/A92/A100 had low levels of expression, did not bind the radioligand, and had a decreased cAMP stimulation. These data indicate the requirement for three or more polysaccharide chains for normal CRFR1 function.
促肾上腺皮质激素释放因子(CRF)1型受体(CRFR1)含有五个潜在的N-糖基化位点:N38、N45、N78、N90和N98。用衣霉素处理表达CRFR1的细胞以阻断受体糖基化。未糖基化的受体不结合放射性配体,并且对CRF的cAMP刺激效力降低。为了确定哪些多糖链参与配体相互作用,利用糖基化共有序列N-X-S/T的定点诱变删除多糖链。对每个糖基化位点进行两组突变:分别将N突变为Q以及将S/T突变为A。单突变体Q38、Q45、Q78、Q90、Q98、A40、A47、A80、A92和A100以及双突变体A40/A47和A80/A100均表达良好,以正常亲和力结合CRF、铃蟾肽(SVG)和尾加压素-I(UTS-I),并高效增加cAMP积累。相比之下,组合突变A80/A92/A100、A40/A80/A92/A100和A40/A47/A80/A92/A100表达水平低,不结合放射性配体,且cAMP刺激降低。这些数据表明正常CRFR1功能需要三条或更多条多糖链。